Sugi Predict

Sugi Predict / Compounds / SCHEMBL3216581

SCHEMBL3216581

SCHEMBL3216581

CN(C)Cc1c[nH]c2ccc(F)cc12

nearest known ligand 0.72

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ MPO P05164 9/20 0.72
▸ SLC6A4 P31645 1/20 0.68
▸ GPR84 Q9NQS5 2/20 0.67
▸ HTR2A P28223 5/20 0.62
▸ KMT2A Q03164 2/20 0.60
▸ TSHR P16473 2/20 0.60
▸ KDM4E B2RXH2 1/20 0.60
▸ MEN1 O00255 1/20 0.60
▸ ALDH1A1 P00352 1/20 0.60
▸ CYP3A4 P08684 1/20 0.60
▸ CYP2D6 P10635 1/20 0.60
▸ CYP2C19 P33261 1/20 0.60
▸ HSD17B10 Q99714 1/20 0.60
▸ TRPM8 Q7Z2W7 1/20 0.59
▸ HTR2C P28335 1/20 0.59
▸ HTR1A P08908 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1241322 0.87 GPR84 (0.67) MPOSLC6A4GPR84HTR2AKMT2A
SCHEMBL2615142 0.84 MPO (1.00) MPOSLC6A4HTR2AKMT2ACYP2D6
SCHEMBL2615141 0.84 MPO (1.00) MPOSLC6A4HTR2AKMT2ACYP2D6
SCHEMBL29904417 0.84 MPO (1.00) MPOSLC6A4HTR2AKMT2ACYP2D6
Hydrochloric Acid SCHEMBL32677865 0.83 MPO (0.97) MPOSLC6A4HTR2AKMT2ACYP2D6
Hydrochloric Acid SCHEMBL32677864 0.83 MPO (0.97) MPOSLC6A4HTR2AKMT2ACYP2D6
SCHEMBL18509057 0.82 MPO (0.62) MPOSLC6A4GPR84HTR2AALDH1A1
SCHEMBL11493839 0.81 CYP2D6 (0.62) MPOSLC6A4HTR2AKMT2ATSHR
SCHEMBL31415109 0.81 CYP2D6 (0.62) MPOSLC6A4HTR2AKMT2ATSHR
SCHEMBL27509657 0.81 MPO (0.53) MPOSLC6A4GPR84HTR2AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 — — US disclosed
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS University of Florida Research Foundation, Incorporation (US) 2024-02-29 — — US disclosed
WO-2022055922-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS EXPANSION THERAPEUTICS, INC. (US) 2022-03-17 — — WO disclosed
US-8258130-B2 Pyrimidine hydrazide compounds as PGDS inhibitors SANOFI (FR) 2012-09-04 — — US disclosed
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2010-02-25 — — US disclosed
EP-2142516-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS Sanofi-Aventis (FR) 2010-01-13 — — EP disclosed
WO-2008121670-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS SANOFI-AVENTIS (FR) 2008-10-09 — — WO disclosed
WO-2008040974-A1 INDOLES FOR USE AS DPP-IV INHIBITORS PEAKDALE MOLECULAR LIMITED (GB) 2008-04-10 — — WO disclosed
US-7208505-B2 β3 adrenergic agonists ELI LILLY AND COMPANY (US) 2007-04-24 — — US disclosed
EP-1421078-B1 INDOLE DERIVATIVES AS BETA-3 ADRENERGIC AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES LILLY CO ELI (US) 2006-09-27 — — EP disclosed
US-20050032873-A1 3-Amino chroman and 2-amino tetralin derivatives WYETH (US) 2005-02-10 — — US disclosed
US-20040242668-A1 3-substituted oxindole beta-3 agonists SALL DANIEL JON (US) 2004-12-02 — — US disclosed
EP-1444224-A2 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS ELI LILLY AND COMPANY (US) 2004-08-11 — — EP disclosed
EP-1421078-A1 BETA-3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2004-05-26 — — EP disclosed
WO-2003016307-A1 β3 ADRENERGIC AGONISTS ELI LILLY AND COMPANY (US) 2003-02-27 — — WO disclosed
WO-2003016276-A2 3-SUBSTITUTED OXINDOLE BETA-3 AGONISTS ELI LILLY AND COMPANY (US) 2003-02-27 — — WO disclosed
US-4283410-A HYPOTENSIVE AGENTS MILES LABORATORIES, INC. (US) 1981-08-11 — — US disclosed
US-4283336-A BY REACTING 3-CYANOMETHYL INDOLE WITH ALKALI METAL BASES TO PRODUCE INTERMEDIATES MILES LABORATORIES, INC. (US) 1981-08-11 — — US disclosed
US-4217357-A Inhibition of thromboxane synthetase with 3-(imidazol-1-ylalkyl)indoles PFIZER INC. (US) 1980-08-12 — — US disclosed
US-3947584-A Novel indolyl alkyl amines, method of producing same, and their use as anorectic agents SIEGFRIED AKTIENGESELLSCHAFT (CH) 1976-03-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067639-A1 SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS FUS, SNRPE, RRBP1 MPO 4272/4885SLC6A4 2410/4885GPR84 3306/4885
US-20050032873-A1 3-Amino chroman and 2-amino tetralin derivatives TPH2, HTR2C, HTR7 MPO 4464/4885SLC6A4 32/4885GPR84 1353/4885
US-20040242668-A1 3-substituted oxindole beta-3 agonists ADRB3, ADRB2, ADRB1 MPO 2672/4885SLC6A4 497/4885GPR84 98/4885
US-20100048568-A1 PYRIMIDINE HYDRAZIDE COMPOUNDS AS PGDS INHIBITORS HRH2, HRH1, HRH4 MPO 885/4885SLC6A4 3553/4885GPR84 135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.